menu
    • menu

    Company profile for Bloomsbury Genetic Therapies

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bloomsbury Genetic Therapies ("Bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare di...
    Bloomsbury Genetic Therapies ("Bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare disease expertise from the Company’s academic founders, Professor Paul Gissen, Professor Manju Kurian, Professor Ahad Rahim and Professor Simon Waddington.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bloomsbury Genetic Therapiesunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    30 Broad Street Great Cambourne Cambridge, CB23 6HJ
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bloomsburygtx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bloomsbury Genetic showcases its First Preclinical Data on Parkinson’s Disease
    Bloomsbury Genetic showcases its First Preclinical Data on Parkinson’s Disease

    10 May 2024

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2024-05-10/bloomsbury-genetic-therapies-showcases-its-first-preclinical-data-on-parkinson-s-disease-program-at-the-american-society-of-gene-cell-therapy-2024-a

    PHARMIWEB
    10 May 2024
    Share Share
    Bloomsbury Genetic Receives Rar Disease from the U.S. FDA for BGT-DTDS
    Bloomsbury Genetic Receives Rar Disease from the U.S. FDA for BGT-DTDS

    03 May 2023

    // BUSINESSWIRE

    https://www.pharmiweb.com/press-release/2023-05-03/bloomsbury-genetic-therapies-receives-rare-paediatric-disease-designation-from-the-us-fda-for-bgt-dtds-for-the-treatment-of-dopamine-transporter-def

    BUSINESSWIRE
    03 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search